In response to the COVID-19 pandemic, the Partnership has formed three emergency response working groups.
These groups are addressing the following areas of need:
- Emergency Access to Treatment/Care Work Group focuses on developing a platform for information-sharing to monitor the situation on the ground and address potential needs, including the provision of MDT and drugs for the treatment of reactions. Through the GPZL and WHO, the latest information on COVID-19 and leprosy drug supply will be provided to National Programme Directors, and further linkages will be sought to share information and knowledge during this challenging time.
- Emergency Advocacy Work Group focuses on supporting the wellbeing of persons affected by leprosy so that no one is left behind. Continuing treatment, basic need fulfillment, and access to social welfare is crucial during the COVID emergency response. This group is facilitating conversions with persons affected organizations and other key stakeholders, and sharing critical information to support persons affected and elevate their challenges and needs.
- Post COVID-19 Work Group focuses on modeling to inform future scenarios, policy development for a post-COVID world, linking leprosy to new funding for health system strengthening, and engaging with other disease and advocacy groups.
Together, these working groups lead action by the leprosy community to protect leprosy prevention and control gains, to support persons affected, and to set a path toward zero leprosy. Sign up for our newsletter to stay updated on their work.
Read more about the Partnership’s foundational working groups, operational from 2018-2019: the Research Agenda Working Group, the Operational Excellence Working Group, and the Partnership and Resource Mobilization Working Group.